Comparative Pharmacology
Head-to-head clinical analysis: ISIBLOOM versus ZOVIA 1 35E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISIBLOOM versus ZOVIA 1 35E 21.
ISIBLOOM vs ZOVIA 1/35E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibits ovulation, alters cervical mucus and endometrial lining.
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets (if included in the pack) or a 7-day pill-free interval. Each tablet contains ethinyl estradiol 0.035 mg and norethindrone 1 mg.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (CrCl <30 mL/min).
Norethindrone: 5-12 hours (terminal elimination half-life, approximately 8 hours). Ethinyl estradiol: biphasic with terminal half-life of 10-20 hours (mean 15 hours). Clinical context: Steady state reached in 5-7 days.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal (approximately 40% as parent drug and metabolites; 20-40% as metabolites; 15-20% as unchanged drug), fecal (30-50% via bile as metabolites), and less than 2% in breast milk.
Category C
Category C
Oral Contraceptive
Oral Contraceptive